Oncology & Cancer

Transfusion dose density affects myelodysplastic syndrome survival

(HealthDay)—Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study ...

Oncology & Cancer

Population mortality affects long-term follow-up of AlloHCT

(HealthDay)—For older patients undergoing allogeneic hematopoietic cell transplantation (alloHCT), a considerable part of total nonrelapse mortality (NRM) is attributable to population mortality, according to a study recently ...

Oncology & Cancer

Cumbersome blood cancer treatment can be postponed

It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents (ESA), which ...

Oncology & Cancer

Response to lenalidomide often suboptimal in MDS/MPN-RS-T

(HealthDay)—Lenalidomide produces hematologic responses in myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) with ring sideroblasts (RS) and thrombocytosis (MDS/MPN-RS-T), although these responses are often ...

Oncology & Cancer

Two studies identify a detectable, pre-cancerous state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood ...

Oncology & Cancer

The Medical Minute: What is myelodysplastic syndrome?

Television journalist and host of "Good Morning America" Robin Roberts announced this week that she has myelodysplastic syndrome, or MDS, an uncommon blood and bone marrow disorder.

page 6 from 7